Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare Part D patients to access certain obesity-indicated GLP-1 medications, including Foundayo, Wegovy, and certain Zepbound formulations, for no more than $50 per month through December 31, 2027
Foundayo showed about 12% body weight reduction in trials, and oral Wegovy came in around 14%
FAQs Q1
LVG, IN, AF, AFHP, LC, CWCK, and JLS reviewed the manuscript for important intellectual content
If you have certain side effects with Vyvanse, such as nausea, dizziness, or diarrhea, drinking alcohol could make them worse
Dr Steward said the rise in off-label prescribing is concerning but the results here should still be enough to ring alarm bells